A range of factors are believed to exert a negative influence on opinions of physicians about generic drugs.The aim of this study was to survey the opinions of primary care doctors on generics, and determine the factors which may affect them. A questionnaire comprising thirty eight questions was distributed among primary care doctors working in seventy out-patient clinics of the Lodzkie province, Poland, during the period of January 1, 2010 - December 31, 2010. A total of 170 of 183 participants completed the survey (average age 48.5; 70.0% women): a 92.9% response rate. While 38.8% of physicians claimed that generics were worse than brand name drugs, 54.1% considered them to be better. However, 36.5% of the doctors did not choose generics for their own use. Two key opinions were identified among the responses concerning the effectiveness of generic drugs: use of generic drugs by the physician (p<0.001), and their opinion that pharmacists do inform patients about generic drugs (p<0.05). Although existing evidence confirms that generic and brand name drugs are equally effective, many physicians doubt this, which prevents them from being used as cost effective drug therapy. In order to increase healthcare savings through the use of generics, these factors should be addressed: for example, convincing a physician to adopt generics for personal use may be an efficient way to support more cost effective treatment of his patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365676PMC
http://dx.doi.org/10.17305/bjbms.2015.1.134DOI Listing

Publication Analysis

Top Keywords

physicians generic
8
primary care
8
care doctors
8
generic drugs
8
factors opinions
4
opinions family
4
family physicians
4
generic
4
generic drugs--a
4
drugs--a questionnaire
4

Similar Publications

In Japan, the regulatory authority approved the drug in September 2023, and on December 20, it became available for prescription country-wide under the health insurance system. However, there are strict patient, physician, and facility requirements for the prescription of Lecanemab, and various problems are anticipated in its future implementation and widespread use in society. Lecanemab is the first anti-Aβ antibody in Japan, and even dementia specialists do not have sufficient knowledge and experience in its introduction, evaluation of efficacy, and evaluation and handling of side effects.

View Article and Find Full Text PDF

Background: African Americans (AA) are underrepresented in Alzheimer's disease (AD) brain donation research, making up approximately 2% of brain donations to the National Alzheimer's Coordinating Center (NACC). Focus groups were conducted to obtain qualitative information to expand upon survey data that was collected previously to gain additional insights into the attitudes of Black∖AA individuals toward brain donation and perceptions of medical research.

Method: A brain donation focus group facilitator guide was created based upon earlier survey findings.

View Article and Find Full Text PDF

Background: Marital status is an important but often overlooked sociodemographic factor that could shape cognitive health in late adulthood. Being married is shown to be linked to lower risk of dementia, but less is understood about underlying mechanisms contributing to this relationship, such as brain reserve (BR) and cognitive reserve (CR). Further, less is known about how living arrangement, independent of marital status, is associated with late-life cognition.

View Article and Find Full Text PDF

Dementia Care Research and Psychosocial Factors.

Alzheimers Dement

December 2024

Prevent Alzheimer's Disease 2020, Inc., Rockville, MD, USA.

Background: With the changing care landscape for early Alzheimer's disease (AD), optimizing the diagnostic and management process is key. This study assessed the correlation between patient and physician characteristics and outcomes related to the diagnosis, referral, and treatment process for early AD in community-based settings.

Method: This cross-sectional study conducted between August and September 2023 abstracted medical chart data for patients aged 50-89 years who were diagnosed with early AD (mild cognitive impairment [MCI] or mild AD) within the past 2 years and had a clinic visit within the past year.

View Article and Find Full Text PDF

Background: Early symptoms of cognitive impairment are frequently undetected. The Davos Alzheimer's Collaborative System Preparedness (DAC-SP) Early Detection program implemented a digital cognitive assessment (DCA) in primary care and other non-specialty settings to increase the rate of detection of cognitive impairment.

Methods: The DAC-SP Early Detection program was initiated in 2021 in seven healthcare systems across six countries.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!